Danielle Campbell - ATyr Pharma, VP Resource
| ATYR Stock | 3.44 0.15 4.56% |
VP
Danielle Campbell is VP Resource of aTyr Pharma,
| Address | 10240 Sorrento Valley Road, San Diego, CA, United States, 92121 |
| Phone | 858 731 8389 |
| Web | https://www.atyrpharma.com |
ATyr Pharma, Management Efficiency
The company has return on total asset (ROA) of (0.3274) % which means that it has lost $0.3274 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6176) %, meaning that it created substantial loss on money invested by shareholders. ATyr Pharma,'s management efficiency ratios could be used to measure how well ATyr Pharma, manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/28/2024, Return On Tangible Assets is likely to drop to -0.44. In addition to that, Return On Capital Employed is likely to drop to -0.55. At this time, ATyr Pharma,'s Other Current Assets are relatively stable compared to the past year. As of 11/28/2024, Non Currrent Assets Other is likely to grow to about 139 K, while Total Assets are likely to drop slightly above 101.9 M.Similar Executives
| Found 4 records | VP Age | ||
| Joanna Totsky | Toro Co | 57 | |
| JD Esq | Church Dwight | 64 | |
| Paulo Bolgar | PACCAR Inc | 56 | |
| Ryan Wentling | Visteon Corp | N/A | |
Management Performance
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.33 |
aTyr Pharma, Leadership Team
Elected by the shareholders, the ATyr Pharma,'s board of directors comprises two types of representatives: ATyr Pharma, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ATyr. The board's role is to monitor ATyr Pharma,'s management team and ensure that shareholders' interests are well served. ATyr Pharma,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ATyr Pharma,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Danielle Campbell, VP Resource | ||
| Jill CPA, Chief Officer | ||
| Jill Broadfoot, Chief Officer | ||
| Jayant MBA, Vice Operations | ||
| Peter Villiger, Vice Development | ||
| Nancy Krueger, General Secretary | ||
| MS MD, CEO President | ||
| XiangLei Yang, Founder | ||
| Ying Buechler, Executive Manufacturing | ||
| Ashlee Dunston, Director Communications | ||
| David King, Scientific Consultant | ||
| Nancy JD, General Secretary | ||
| Leslie Nangle, Vice Research |
ATyr Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ATyr Pharma, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.33 | ||||
| Operating Margin | (106.33) % | ||||
| Current Valuation | 79.38 M | ||||
| Shares Outstanding | 75.8 M | ||||
| Shares Owned By Insiders | 2.39 % | ||||
| Shares Owned By Institutions | 64.48 % | ||||
| Number Of Shares Shorted | 2.11 M | ||||
| Price To Book | 1.76 X | ||||
| Price To Sales | 244.92 X |
Pair Trading with ATyr Pharma,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ATyr Pharma, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ATyr Pharma, will appreciate offsetting losses from the drop in the long position's value.Moving together with ATyr Stock
| 0.78 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against ATyr Stock
| 0.87 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.78 | NKTX | Nkarta Inc Buyout Trend | PairCorr |
| 0.77 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.74 | PEPG | PepGen | PairCorr |
| 0.62 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
The ability to find closely correlated positions to ATyr Pharma, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ATyr Pharma, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ATyr Pharma, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling aTyr Pharma, to buy it.
The correlation of ATyr Pharma, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ATyr Pharma, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if aTyr Pharma, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ATyr Pharma, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ATyr Stock Analysis
When running ATyr Pharma,'s price analysis, check to measure ATyr Pharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ATyr Pharma, is operating at the current time. Most of ATyr Pharma,'s value examination focuses on studying past and present price action to predict the probability of ATyr Pharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ATyr Pharma,'s price. Additionally, you may evaluate how the addition of ATyr Pharma, to your portfolios can decrease your overall portfolio volatility.